Biotech Archives - Page 131 of 795

2 minute read

Acadia Healthcare Enters Into A Joint Venture Partnership With Ascension Seton To Expand Behavioral Health Services In Austin, Texas

January 9, 2:19 PM

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) today announced that it has formed a joint venture partnership with Ascension Seton, one of the leading, integrated healthcare systems in Austin, Texas, and a part of the

ACHC

3 minute read

Short Seller’s Bombshell Report Rattles Grifols: Stock Chart Points To Potential Further Decline

By Piero Cingari

January 9, 2:09 PM

Grifols, the Spanish multinational pharmaceutical titan involved into blood-related medicines, saw its shares fall by 24% on Tuesday.

EWP

1 minute read

Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year

By Vandana Singh

January 9, 1:58 PM

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product

SRPT

3 minute read

Vertex Announces Approval Of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Kingdom Of Saudi Arabia

By Benzinga Newsdesk

January 9, 1:44 PM

- CASGEVY™ is first medicine ever to be evaluated through the SFDA's Breakthrough Medicines Program -- First treatment center in Saudi Arabia has been activated -Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

VRTX

2 minute read

Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?

By Vandana Singh

January 9, 1:12 PM

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients un

MCRB

4 minute read

Biomea Fusion Highlights Recent Updates And Anticipated 2024 Corporate Milestones At 42nd Annual J.P. Morgan Healthcare Conference

By Benzinga Newsdesk

January 9, 12:04 PM

Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in

BMEA

5 minute read

Kymera Therapeutics Outlines Key 2024 Objectives And Strategy To Progress Leading Portfolio Of Immunology And Oncology Programs, Co Well-Capitalized, With Cash In Excess Of $745M And Expected Runway Into The First Half Of 2027

By Benzinga Newsdesk

January 9, 10:19 AM

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025 STAT6 oral degrader KT-621, with

KYMR

1 minute read

Grifols Stock Tanks, Short Seller Accuses Of Overstating Profits, Concerning Allegations About Financial Health

By Vandana Singh

January 9, 10:07 AM

Gotham City Research released a short report on Grifols SA (NASDAQ:

GRFS

3 minute read

Edgewise Therapeutics Highlights 2023 Accomplishments And Anticipated Milestones For 2024 At The 42nd Annual J.P. Morgan Healthcare Conference

By Benzinga Newsdesk

January 9, 9:49 AM

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 10:30 am PT (1:30 pm ET), and a live webcast will

EWTX

1 minute read

Lexaria Bioscience Corp. Improves Delivery, Efficacy Of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

By Benzinga Newsdesk

January 9, 9:47 AM

Lexaria Bioscience Corp. (NASDAQ:LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a

LEXX